Accelerate Diagnostics, Inc.
AXDX · NASDAQ
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.04 | 0.02 | 0.02 |
| FCF Yield | -18.12% | -7.24% | -28.12% | -52.45% |
| EV / EBITDA | -18.21 | -8.05 | -7.49 | -3.93 |
| Quality | ||||
| ROIC | -54.35% | -57.53% | -80.72% | -59.95% |
| Gross Margin | 15.94% | 28.77% | 22.64% | 24.75% |
| Cash Conversion Ratio | 0.53 | 0.21 | 0.65 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.83% | -3.25% | -2.78% | -0.22% |
| Free Cash Flow Growth | -64.28% | 59.33% | 15.39% | -13.99% |
| Safety | ||||
| Net Debt / EBITDA | -11.80 | -3.86 | -4.16 | -2.36 |
| Interest Coverage | -1.77 | -2.40 | -3.32 | -4.15 |
| Efficiency | ||||
| Inventory Turnover | 0.83 | 0.71 | 0.72 | 0.68 |
| Cash Conversion Cycle | -10.64 | -12.41 | 48.11 | -7.81 |